$63.2m contributed to the World Health Organization’s Pandemic Influenza Preparedness Framework since 2012 Vaccine access, alongside surveillance and testing, is critical for pandemic preparedness and provides reassurance to governments and their populations alike. Lorna Meldrum, Vice President Commercial Operations, International & Pandemic Response, CSL Seqirus Protecting Communities Through Regional Collaboration Supporting The Next Generation of Vaccine Researchers Through its support of the European Scientific Working Group on Influenza’s Early Career Scientist Award, CSL Seqirus is helping recognise and encourage emerging researchers whose work is advancing influenza science and contributing to the development of more effective vaccines. In 2025, Dr Marios Koutsakos from the Doherty Institute, University of Melbourne, received the award for his research into how the immune system recognises influenza B viruses. His work is helping deepen understanding of immune responses and could contribute to the development of more effective influenza vaccines. By investing in emerging scientific talent and fostering collaboration between academia and industry, CSL Seqirus is helping advance the research needed to tackle one of the world's most persistent infectious diseases. In FY26, CSL Seqirus announced two landmark partnerships with the Pan American Health Organization (PAHO) to strengthen influenza prevention and pandemic preparedness across Latin America and the Caribbean. Through a long-term agreement with PAHO's Revolving Fund, CSL Seqirus will expand access to its differentiated seasonal influenza vaccine portfolio while working with long-standing partner Sinergium Biotech to localise vaccine filling and distribution in the region, helping build sustainable regional manufacturing capability and supply resilience. CSL Seqirus also signed a pioneering pandemic preparedness agreement with PAHO, reserving 14 million doses of pandemic influenza vaccine for participating member states in the event of a WHO-declared pandemic, supporting faster and more equitable access to vaccines. Partnering to Improve Equitable Access During a Pandemic Influenza pandemics do not respect borders, making equitable access to vaccines a critical component of global health security. CSL Seqirus supports pandemic preparedness through its global manufacturing network, scientific expertise and long-standing partnerships with governments, public health agencies and international organisations. A key part of this commitment is CSL Seqirus' participation in the World Health Organization's (WHO) Pandemic Influenza Preparedness (PIP) Framework. Through this unique public-private partnership, CSL Seqirus has pledged to make available 10% of its real-time pandemic influenza vaccine production to the WHO for deployment to developing countries during a declared influenza pandemic, helping strengthen global preparedness and expand access to vaccines for populations that might otherwise face barriers to timely supply. CSL IMPACT REPORT 2026 | 19
RkJQdWJsaXNoZXIy MjE2NDg3